top of page

T-Cell Technology & Development 

The IL-7 project was founded in the early 2000s by a French team under the name of Cytheris. It was resumed in 2013 by US investors.

Early support came from numerous academic and public organizations with collaboration at preclinical and clinical levels: NCI, NIAID, INSERM, MSKCC, FHCRC, ANRS, Institut Pasteur.

More than 60 international publications have been produced.


The project is currently involved in many international collaborations for the clinical development of IL-7 immunotherapy in Oncology and Infectious diseases.

IL-7 provides a global T-cell support for Immunotherapies

Gradient pink to blue

RevImmune is Headquartered in Bethesda, Maryland, USA, with a fully operational subsidiary in Paris, France

Michel Morre

DVM, MSc, C.S.O.

Chief Scientific Officer of RevImmune.

Ex Postdoctoral fellow at MIT, Ex-innovation Director at Sanofi, Founder past President and Chief Executive Officer of Cytheris (until 10/2011)

Frederique Berbille

MSc Health Sciences, D.C.O.

Director of Clinical Operations at RevImmune

With a past experience of clinical development at Pfizer, Organon, Quintiles

Anne Gregoire

MSc PhD, D.P.D

Director of Process Development

ex Postdoctoral fellow at LSCG “CNRS” - Nancy I. Anne has a 20 years experience of biotech process development mainly at Cytheris and then RevImmune.

Sonia Letestu

Biotech Engineer

Deputy Director of Process Development

Ex project manager and team leader at Glenmark and Ablynx

Key Collaborations

University of Washington Logo
University of Florida logo
WUSTL School of Medicine Logo

Our project is supported by key opinion leaders from a range of universities and institutions.


Richard Hotchkiss MD

Professor of Anesthesiology Washington University School of Medicine, St Louis, MO, USA

Kenneth Remy MD

Assistant Professor of Pediatrics, Critical Care Medicine

Lyle L. Moldawer Ph.D.

Professor of Surgery Sepsis and Critical Illness Research Center University of Florida College of Medicine


Mac Cheever MD

Professor Clinical Research Division, Fred Hutch Director for the Cancer Immunotherapy Trials Network (CITN)

bottom of page